

Patient characteristics and utilization patterns of romosozumab in routine clinical practice: a European, multi-country, non-interventional study (PRIME)

First published: 15/10/2024

Last updated: 12/05/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000000343

Study ID

1000000343

DARWIN EU® study

No

Study countries

☐ Belgium

☐ Germany

☐ Greece

- ☐ Italy
 - ☐ Spain
 - ☐ Sweden
 - ☐ Switzerland
 - ☐ United Kingdom
-

Study status

Ongoing

Contact details

Study institution contact

UCB Cares UCBCares.global@ucb.com

Study contact

UCBCares.global@ucb.com

Primary lead investigator

Alireza Moayyeri

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 29/07/2024

Study start date

Planned: 25/03/2025

Actual: 02/04/2025

Date of final study report

Planned: 04/01/2027

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

UCB Biopharma SRL

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Other

If 'other', further details on the scope of the study

Patient characteristics

Study drug and medical condition

Medicinal product name

EVENITY

Study drug International non-proprietary name (INN) or common name

ROMOSUZUMAB

Anatomical Therapeutic Chemical (ATC) code

(M05BX06) romosozumab

romosozumab

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes